A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is a phase I/II, open-label study to evaluate the safety, tolerability, pharmacokinetics
and anti-tumor activity of BPI-361175 tablets in patients with advanced solid tumors
including advanced Non-small cell Lung cancer (NSCLC).This is a three-stage study, consisting
of Phase Ia dose escalation, Phase Ib dose expansion and pivotal Phase II Study. The pivotal
Phase II study will be designed based on data generated from the Phase I studies.